CASH Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 64
Average round size
The average size of a deal this fund participated in
Portfolio companies 54
Rounds per year 5.82
Lead investments 19
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 3
Key employees 1

Areas of investment

  • Health Care
  • Biotechnology
  • Information Technology
  • Manufacturing
  • Medical

In 2011 was created CASH Capital, which is appeared as VC. The main office of represented VC is situated in the Beijing. The venture was found in Asia in China.

Among the most popular portfolio startups of the fund, we may highlight YiXue Squirrel AI, KBP Biosciences, Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular fund investment industries, there are Software, Robotics.

The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2019. Considering the real fund results, this VC is 40 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the CASH Capital, startups are often financed by Source Code Capital, Vision Plus Capital, Nanjing Gaoke. The meaningful sponsors for the fund in investment in the same round are BioTrack Capital, Matrix Partners China, IDG Capital. In the next rounds fund is usually obtained by Matrix Partners China, Maintrend Capital, China Creation Ventures (CCV).

We also calculated 1 valuable employee in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of CASH Capital:
Typical Co-investors
CASH Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after CASH Capital:
There are no funds here. If we find new data, we will add it here.

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$7M17 Feb 2022 Shenzhen, Guangdong, China

ImmuneOnco Biopharma

Health Care
$100M01 Jan 2022 Shanghai, China

Shanghai Union Technology

3D Printing
$30M21 Dec 2021 -

Guizhou Core Long March Technology (Marching Power)

Information Technology
Product Design
$77M16 Dec 2021 Guiyang, Guizhou, China


Medical Device
19 Nov 2021 Suzhou, Jiangsu, China

Hzymes Biotechnology

$123M10 Nov 2021 Wuhan, Hubei, China

Bohai New Enzyme

$123M05 Nov 2021 Shanghai, China

OnQuality Pharmaceuticals

$20M31 Mar 2021 Shanghai, Shanghai, China

Vision Medicals

Health Care
$30M04 Feb 2021 Yuexiu District, Guangdong Province, China
OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent CASH Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: